Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Daré Bioscience, Inc. Expands Leadership Team, Appointing David Friend, Ph.D. to Chief Scientific Officer
SAN DIEGO , June 06, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of David Friend , Ph.D., to the newly created role of Chief Scientific Officer (CSO). “We are excited to add Dr.
View HTML
Toggle Summary Daré Bioscience, Inc. Expands Leadership Team, Appointing Mary Jarosz, RPh, to Global Head of Regulatory Affairs
SAN DIEGO , June 04, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of Mary Jarosz , RPh, to the newly created role of Global Head of Regulatory Affairs.
View HTML
Toggle Summary EY Announces that Sabrina Martucci Johnson, CEO of Daré Bioscience, Inc., is an Entrepreneur Of The Year® 2018 Award Finalist in San Diego
SAN DIEGO , May 16, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company focused on women’s sexual and reproductive health, announced today that President and CEO Sabrina Martucci Johnson is a finalist for the Entrepreneur Of The Year ®
View HTML
Toggle Summary Daré Bioscience, Inc. Announces Trial Initiation for Ovaprene® Non-Hormonal Monthly Contraceptive Candidate
SAN DIEGO , May 15, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company focused on women’s sexual and reproductive health, announced today the initiation of its post-coital test (PCT) clinical trial for its lead product candidate
View HTML
Toggle Summary Daré Bioscience, Inc. Expands Leadership Team, Appointing John Fair to Chief Business Officer
SAN DIEGO , May 08, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced it has appointed Mr. Fair to the newly created position of Chief Business Officer. Mr. Fair’s role will include business and corporate development,
View HTML
Toggle Summary Daré Bioscience, Inc. Enters into Agreement to Acquire Product to Address Vulvar and Vaginal Atrophy in Hormone Receptor-Positive Breast Cancer Patients
Agreement intends to broaden Company’s product portfolio within women’s reproductive health with novel clinical candidate, positioning Company with first in class candidates in contraception, sexual health and vaginal health SAN DIEGO , May 07, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.
View HTML
Toggle Summary Daré Bioscience announces funding award to further the development of Ovaprene™ from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
SAN DIEGO , April 30, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it received a Notice of Award for the first $224,665 of the anticipated $1.9 million in grant funding from the Eunice Kennedy Shriver
View HTML
Toggle Summary Daré Bioscience, Inc. Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform
The intravaginal ring technology platform is designed to deliver targeted and sustained pharmaceutical formulations addressing unmet needs in women’s health SAN DIEGO , April 25, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company
View HTML
Toggle Summary Jessica Grossman, M.D., Joins Daré Bioscience Board of Directors
SAN DIEGO , April 11, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of Jessica Grossman , M.D., to its board of directors. Dr. Grossman is currently the CEO of Medicines360, a global nonprofit
View HTML
Toggle Summary Daré Bioscience, Inc. Reports 2017 Financial Results and Provides Business Update
-Conference Call and Webcast Today, April 2 nd , at 4:30 PM Eastern Time - SAN DIEGO , April 02, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.  (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced financial results for the full year ended December 31, 2017.
View HTML